CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it has entered into a License, Supply, and Commercialization Agreement with Kye Pharmaceuticals Inc., ("Kye" or "Kye Pharmaceuticals") granting Kye the exclusive Canadian commercial ri ...

CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its second quarter 2024 financial results after the market close on Wednesday, August 7, 2024. Catalyst's management team will host a conference call and webcast on Thu ...

CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its second quarter 2024 financial results after the market close on Wednesday, August 7, 2024. Catalyst's management team will host a conference call and webcast on Th ...

Catalyst Pharmaceuticals, Inc. (CPRX) reported adjusted earnings of 38 cents per share for the first quarter of 2024, beating the Zacks Consensus Estimate of 34 cents. The company reported adjusted earnings of 41 cents in the year-ago quarter. Total revenues amounted to $98.5 million in the reported quarter, which surpassed the Zacks Consensus Estimate of $97 million. Total product revenues climbed 15.4% to $98.4 million, from the year-ago quarter’s $85.3 million. The top line primarily comprised product sa ...

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Michael Kalb - Chief Financial Officer Richard Daly - President and Chief Executive Officer Jeffrey Del Carmen - Chief Commercial Officer Steven Miller - Chief Operating Officer and Chief Scientific Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Jason Gerberry - Bank of America Joe Catanzaro - Piper Sandler Operator Greetings, and welcome to the Catalyst Pharmace ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 76-0837053 (State or other jurisdiction of (IRS Empl ...

Catalyst Pharmaceutical (CPRX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on May 8, 2024, might help the stock move higher if these key numbers are bette ...

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 25, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May 2023 financial key figures: Revenue from contracts with customers of CHF 103.4 million (2022: CHF 7.5 million) Net result of CHF 54.8 million (2022: CHF -71.1 million) Cash flow from operating activities ...

Investing in discounted stocks for big gains is a time-tested strategy. Although short-term market fluctuations may capture the attention of many, companies with sustainable growth prospects often prove to be the most lucrative investments over time. Focusing on businesses with competitive advantages, healthy financials and products customers love can position investors to benefit from compounding long-term growth. These companies often have a consistent revenue growth track record and a clear vision for th ...

AGAMREE® is U.S. FDA approved and now available in the United States for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older This follows the first commercial launch of AGAMREE in Germany in January 2024 by Santhera AGAMREE is the first DMD treatment approved across the U.S., EU and UK Pratteln, Switzerland, March 14, 2024 – Santhera Pharmaceuticals (SIX: SANN) is pleased to note the launch of AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in ...